descriptionPublicationkeyboard_double_arrow_right Article 01 Dec 2011 English Publisher:Elsevier BVJournal:Bioorganic & Medicinal Chemistry Letters, volume 21, pages 7,440-7,446 (issn: 0960-894X,

Authors: Helen Edwards; Antonio Mete; Keith Bowers; Vince Russell; Rhonan Ford; Barry Teobald; Ian Millichip; +4 Authors

doi: 10.1016/j.bmcl.2011.10.002

pmid: 22047691

The discovery of AZD9164, a novel muscarinic M3 antagonist

- Summary
- Subjects
- Related research
  (1)
- Metrics

Abstract

The optimization of a new series of muscarinic M(3) antagonists is described, leading to the identification of AZD9164 which was progressed into the clinic for evaluation of its potential as a treatment for COPD.

Related Organizations

Loughborough University
United Kingdom
AstraZeneca (United Kingdom)
United Kingdom

Keywords

Receptor, Muscarinic M3, Quinuclidines, Drug Evaluation, Preclinical, Blood Proteins, Muscarinic Antagonists, Pulmonary Disease, Chronic Obstructive, Structure-Activity Relationship, Piperidines, Humans, Protein Binding

1 Research products, page 1 of 1

BindingDB Entry 50041958: The discovery of AZD9164, a novel muscarinic M3 antagonist.
2013IsSourceOf

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	17
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average